5th Annual Healthcare Conference
a
Conf Logo


Logo


Essner Robert A. Essner
Former Chairman & CEO  Wyeth

Executive-in-Residence Columbia Business School
Ludwig Edward J. Ludwig ('75)
Chairman & CEO
BD (Becton Dickinson)


pharmabiotech

PHARMA/BIOTECH PANEL Reassessing the Business Model as Top-Line Growth Slows

• What strategies is Big Pharma employing to enhance productivity and reduce costs in line with slowing top-line growth?

• What R&D and portfolio optimization strategies are being pursued?

• Given enhanced focus on oncology, what changes do you expect in the regulatory, pricing and reimbursement environment for products in this category?

Why have many Big Pharma companies stayed “pure plays” while others seek to diversify away from branded Rx drugs?

• Has the business model for small/mid-size biotechnology companies changed materially given current regulatory and pricing environment?

medicaldevices

MEDICAL DEVICES PANEL “Growth Prospects & Opportunities in an Increasingly Challenging Regulatory & Competitive Environment”

• What are the relative growth prospects for the major segments within the medical device industry (interventional cardiology, orthopedics, diagnostics, etc.)?

• How is the changing regulatory and pricing/reimbursement environment in the medical device industry affecting the launch of new products?

• How has the business model for early-stage device companies changed given the current environment?

• How is the relationship between physician/surgeon and company sales representatives evolving in orthopedics and other medical device segments?

• Which areas represent the greatest opportunity for “convergence” between devices/ diagnostics and drugs?


Payorprovider

PAYOR/PROVIDER PANEL Evolving Paradigms in Managing Costs/ Outcomes – Impact of November Elections

• Which strategies are employers, insurers and providers pursuing to slow the growth of employee healthcare costs and improve health outcomes?

• What actions are major hospitals taking to reduce medical errors and improve outcomes?

• How effective have consumer-driven healthcare initiatives been?

• Why is the healthcare industry slow to adopt information technology, and what can be done to overcome such barriers?

• How will the November election affect potential legislation impacting the cost and provision of care in the US?

M&A

MERGERS AND ACQUISITIONS PANEL “Dealmaking Strategies to Enhance Competitive Position”

• What is the likelihood of further transforming Big Pharma mergers?  Will “pure play” Big Pharma companies seek to diversify into other businesses through large-scale acquisitions?

• Will we continue to see Big Pharma buying biotech – using what criteria and deal parameters? 

• Which sectors of the medical device and diagnostics area will experience the greatest M&A activity and why?

• Do you expect further consolidation among providers and payors?  Which other healthcare service areas are primed for enhanced M&A activity and why?

• What are private equity firms’ current investment strategies in the healthcare sector? 

• How are successful companies organized to best identify, pursue, negotiate, and execute M&A and other business development initiatives?

lifesciences

LIFE SCIENCES VENTURES PANEL “Current Strategies and Models for Life Science Venture Firms and Entrepreneurs"

• What are the current investment strategies of life science venture capital firms?

• Is the recent decline in funding “idea companies” a short-term phenomenon or fundamental change in strategy?

• How do corporate and VC firms differ in their respective focus and approach?

• How have exit options changed given current disruption in the capital markets?

• What are some of the “lessons learned” from life science entrepreneurs in building successful early-stage biotechnology and medical device companies?

EMERGING MARKETS PANEL “Opportunities and Challenges for Global Healthcare Companies in BRIC and Other Regions”

• What are the opportunities & challenges of investing in, and marketing to, BRIC countries (Brazil, Russia, India, China) and other emerging markets for global healthcare companies?

• Is the potential to enter these markets worth the risk to intellectual property?

To what extent do global healthcare companies have a responsibility for addressing global health challenges (AIDS, TB, malaria, etc.)?

• What is the record of success of public-private partnerships in combating disease in developing countries?


career

CAREER STRATEGIES PANEL “Current Hiring/Talent Deployment Needs of Leading Healthcare Companies and Career Strategies”

•  What is the current hiring environment for key segments of the healthcare industry (pharma, med tech, payor/provider, healthcare consulting, investment banking, etc.)?

•  What is the likely hiring environment for MBAs (in healthcare) in 2009?

 How are leading healthcare companies maximizing the value of leadership capital?

•  What are the key professional and personal characteristics leading healthcare companies are seeking in experienced new hires?

•  How should employees respond to dislocations caused by cost reduction programs, acquisitions, etc.?

© 2008 Columbia Business School :: Healthcare Industry Association